Oral delivery of DNA construct using chitosan nanoparticles to protect the shrimp from white spot syndrome virus (WSSV)

Rajeshkumar, S.; Venkatesan, C.; Sarathi, M.; Sarathbabu, V.; Thomas, John; Basha, K. Anver; Hameed, A.S. Sahul

doi:10.1016/j.fsi.2009.01.003

Cited by 147 publications

(49 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyclodextrin-based nanoparticles contain polycation nanoparticles and like dynamic polyconjugates, involve targeted delivery and endosomal escape mechanisms [63]. Atelocollagen and chitosan are two additional polymer-type approaches that have also been reported to effectively deliver siRNA in vivo [69,142,148,181].…”

Section: Polymer Complexesmentioning

confidence: 99%

“…In almost all cases reported, survival increased following the administration of dsRNA, triggering of the RNAi pathway. RNAi has down regulated White Spot Syndrome Virus and allowed a 85 % reduction in mortality when targeting the VP28 envelope gene, suggested to play a role in WSSV infection [114,148]; 78 % reduction in mortality when targeting RR2 ribonucleotide reductase; 70 % reduction in mortality against VP19 envelope gene [154]; 47 % reduction in mortality against viral ubiquitin ligase [62]; 44 % reduction in mortality when antagonistic to the DNA polymerase. Similarly, when yellow head virus was down regulated by attacking its protease gene and a host host Rab7 GTPase, mortality was reduced by 90 % [143].…”

Section: Rnai With Special Reference To Controlling Viruses In Crustaceamentioning

confidence: 99%

“…A seminal piece of research by Rajeshkumar et al [148], showed that after 1 week of dietary uptake of chitosanbound plasmid against WSSV VP28, there was relatively long term protection. Challenge with WSSV 1, 2, and 3 week after cessation of administration of the dsRNA lead to survival of 85, 65 and 50 % respectively.…”

Section: Dose and Timing Of Prophylactic Delivery Of Rnaimentioning

confidence: 99%

See 2 more Smart Citations

RNA Interference with Special Reference to Combating Viruses of Crustacea

Fauce

Owens

2012

Indian J. Virol.

View full text Add to dashboard Cite

RNA interference has evolved from being a nuisance biological phenomenon to a valuable research tool to determine gene function and as a therapeutic agent. Since pioneering observations regarding RNA interference were first reported in the 1990s from the nematode worm, plants and Drosophila, the RNAi phenomenon has since been reported in all eukaryotic organisms investigated from protozoans, plants, arthropods, fish and mammals. The design of RNAi therapeutics has progressed rapidly to designing dsRNA that can specifically and effectively silence disease related genes. Such technology has demonstrated the effective use of short interfering as therapeutics. In the absence of a B cell lineage in arthropods, and hence no long term vaccination strategy being available, the introduction of using RNA interference in crustacea may serve as an effective control and preventative measure for viral diseases for application in aquaculture.

show abstract

Section: Polymer Complexesmentioning

confidence: 99%

Section: Rnai With Special Reference To Controlling Viruses In Crustaceamentioning

confidence: 99%

Section: Dose and Timing Of Prophylactic Delivery Of Rnaimentioning

confidence: 99%

See 1 more Smart Citation

RNA Interference with Special Reference to Combating Viruses of Crustacea

Fauce

Owens

2012

Indian J. Virol.

View full text Add to dashboard Cite

show abstract

“…have been performed in mice (35,42,46,47,134,136,137) and rats (61,74), it becomes very difficult to extrapolate these results to their in vivo performance in humans. In addition, very few studies have addressed the toxicity related issues which remains a major concern with these newly emerged nanoparticulate systems (46,47,(136)(137)(138)(139)(140). Perhaps, more preclinical studies in the coming years may provide an important insight on the role of CS-NPs for the delivery of proteins, peptides and drugs and would initiate the need of clinical trials in humans.…”

Section: Current Perspective Of Chitosan Nanoparticles For Clinical Usementioning

confidence: 99%

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

2010

View full text Add to dashboard Cite

Abstract. Nanoparticles composed of naturally occurring biodegradable polymers have emerged as potential carriers of various therapeutic agents for controlled drug delivery through the oral route. Chitosan, a cationic polysaccharide, is one of such biodegradable polymers, which has been extensively exploited for the preparation of nanoparticles for oral controlled delivery of several therapeutic agents. In recent years, the area of focus has shifted from chitosan to chitosan derivatized polymers for the preparation of oral nanoparticles due to its vastly improved properties, such as better drug retention capability, improved permeation, enhanced mucoadhesion and sustained release of therapeutic agents. Chitosan derivatized polymers are primarily the quaternized chitosan derivatives, chitosan cyclodextrin complexes, thiolated chitosan, pegylated chitosan and chitosan combined with other peptides. The current review focuses on the recent advancements in the field of oral controlled release via chitosan nanoparticles and discusses about its in vitro and in vivo implications.

show abstract

“…This can be overcome by the simple usage of nanotechnology in drug delivery. use of nanoparticle carriers like chitosan and poly-lactide-co-glycolide acid (PLGA) 72 of vaccine antigens together with mild inflammatory inducers may give a high level of protection to fishes and shellfishes not only against bacterial diseases, but also from certain viral diseases with vaccine-induced side effect. Further, the mass vaccination of fish can be done using nanocapsules containing nano-particles.…”

Section: Remediation Of Adverse Drug Effectsmentioning

confidence: 99%